Your browser doesn't support javascript.
loading
Recombinant immunotoxins development for HER2-based targeted cancer therapies.
Mahmoudi, Reza; Dianat-Moghadam, Hassan; Poorebrahim, Mansour; Siapoush, Samaneh; Poortahmasebi, Vahdat; Salahlou, Reza; Rahmati, Mohammad.
Afiliación
  • Mahmoudi R; Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Dianat-Moghadam H; Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran. Dianath@tbzmed.ac.ir.
  • Poorebrahim M; Targeted Tumor Vaccines Group, Clinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Siapoush S; Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Poortahmasebi V; Department of Bacteriology and Virology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Salahlou R; Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Rahmati M; Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran. rahmatimo@tbzmed.ac.ir.
Cancer Cell Int ; 21(1): 470, 2021 Sep 06.
Article en En | MEDLINE | ID: mdl-34488747
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancer Cell Int Año: 2021 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancer Cell Int Año: 2021 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Reino Unido